Button Text
About Us
We are committed to developing the transformative biotherapeutics with T cell engaging bispecific antibodies

LintonPharm Co., Ltd. is a clinical-stage, research-oriented biopharmaceutical company committed to developing innovative T cell engaging bispecific antibodies with the goal of becoming the worldwide leader in CD3 bispecific antibody. LintonPharm, in collaboration with Lindis Biotech, is developing Catumaxomab for use in a broad range of cancers globally. Additionally, LintonPharm is developing a next generation bispecific antibody platform to provide a more robust manufacturing and drug design and increased flexibility to individualize the design of each molecule. The current pipeline includes several treatments in development for solid tumors.

We have an industry-leading management team and scientific advisors with rich experience in cancer immunotherapy especially T cell engagers, and with antibody engineering, advancing drug candidates from early-stage research to clinical trials and regulatory approval.

Guided by our core value – leading immunotheraqpy with unique CD3 platform, we relentlessly build on our expertise in cancer immunology and leading-edge technologies in pursuit of transformative treatments for cancer patients. We approach each day with our commitment and passion to improve lives of patients, and a sense of humility, recognizing that our strength resides in the diversity of our journeys and the opportunity to learn from each other.

Awards & Milestones
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019-2017

· Enrollment of phase I clinical trial of Catumaxomab in patients with non-muscle invasive bladder cancer completed
· The phase I clinical trial of Catumaxomab in patients with advanced gastric cancer has been completed in the Asia-Pacific region (China, Taiwan China and South Korea), and the pivotal phase III trial for regulatory will be conducted

· "2021 China Biotech 50" was awarded by KPMG
· "2021 Guangzhou Future Star" was awarded
· The preliminary clinical result of Catumaxomab, <Global multi-center phase I trial of the intraperitoneal infusion of anti-EpCAM x anti-CD3 bispecific antibody Catumaxomab for advanced gastric carcinoma with peritoneal metastasis> was released at 2022 ASCO Annual Meeting
· "2021 Guangzhou Unicorn Innovative Company" was awarded

· Enrollment for stage 1 of the global  phase III trial of Catumaxomab in patients with advanced gastric cancer completed

· "Aggressive Enterprise Award" of top 50 innovative biotech companies in the Greater Bay Area was awarded
"The strongest leader in science and technology" of 2021 Guangzhou pre-IPO company was awarded
First patient dosed in the clinical trial of Catumaxomab for non-muscle-invasive bladder cancer
· "Potential Unicorn Enterprise" was awarded by Huangpu District Guangzhou Development Zone
· Cohort A enrollment in stage 1 of the global phase III trial of Catumaxomab for advanced gastric cancer completed
· The clinical trial of Catumaxomab for non-muscle invasive bladder cancer was authorized by NMPA

· First patient dosed in the global phase Ⅲ trial of Catumaxomab for advanced gastric cancer
· The clinical trial of Catumaxomab for advanced gastric cancer was authorized by NMPA, TFDA and MFDS

· IND application of Catumaxomab for the treatment of advanced gastric cancer submitted to NMPA, TFDA and MFDS.
· LintonPharm was founded